Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy

Nephrology Dialysis Transplantation

Volumn 26, Issue 2, 2011, Pages 620-627

  Eilertsen, Gro Østli ^a   Fismen, Silje ^b   Hanssen, Tor Arne ^b   Nossent, Johannes C ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

antibodies; epidemiology; hypertension; lupus nephritis; survival

Indexed keywords

ALBUMIN; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LA ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY;

ADULT; ALBUMIN BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROSIS; NORWAY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RISK REDUCTION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; URINARY CAST;

ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTINUCLEAR; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; NORWAY; PREVALENCE; RISK FACTORS;

EID: 78650684376     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq435     Document Type: Article

References (40)

1. Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338: 1359-1368
2. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424
3. Holers VM, Girardi G, Mo L et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-220 (Pubitemid 34461265)
4. Seligman VA, Lum RF, Olson JL et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002; 112: 726-729
5. Bastian HM, Roseman JM, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 152-160
6. Patel M, Clarke AM, Bruce IN et al. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum 2006; 54: 2963-2969
7. Eilertsen GO, Becker-Merok A, Nossent JC. The influence of the 1997 Updated Classification Criteria for Systemic Lupus Erythematosus: epidemiology, disease presentation, and patient management. J Rheumatol 2009; 36: 552-559
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
9. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277
10. Nossent HC. Systemic lupus erythematosus in the Arctic region of Norway. J Rheumatol 2001; 28: 539-546
11. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640
12. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
13. Austin HA III, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550
14. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250
15. Austin HA III, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75: 382-391
16. Bernatsky S, Clarke A, Abrahamowicz M et al. A comparison of prospective and retrospective evaluations of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. J Rheumatol 2005; 32: 820-823
17. Brandt JT, Triplett DA, Alving B et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific 626 G.Ø. Eilertsen et al. and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190
18. Stahl-Hallengren C, Jonsen A, Nived O et al. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000; 27: 685-691
19. Iseki K, Miyasato F, Oura T et al. An epidemiologic analysis of endstage lupus nephritis. Am J Kidney Dis 1994; 23: 547-554
20. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533
21. Haugbro K, Nossent JC, Winkler T et al. Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis 2004; 63: 386-394
22. Riboldi P, Gerosa M, Moroni G et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 2005; 38: 39-45
23. Rekvig OP, Nossent JC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? Arthritis Rheum 2003; 48: 300-312
24. McClain MT, Arbuckle MR, Heinlen LD et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50: 1226-1232
25. Moroni G, Ventura D, Riva P et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004; 43: 28-36
26. Molino C, Fabbian F, Longhini C. Clinical approach to lupus nephritis: recent advances. Eur J Intern Med 2009; 20: 447-453
27. Atsumi T, Khamashta MA, Haworth RS et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum 1998; 41: 800-807
28. Kant KS, Dosekun AK, Chandran KG et al. Deficiency of a plasma factor stimulating vascular prostacyclin generation in patients with lupus nephritis and glomerular thrombi and its correction by ancrod: in-vivo and in-vitro observations. Thromb Res 1982; 27: 651-658
29. Kant KS, Pollak VE, Dosekun A et al. Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod. J Lab Clin Med 1985; 105: 77-88
30. Pierucci A, Simonetti BM, Pecci G et al. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med 1989; 320: 421-425
31. Tomasoni S, Noris M, Zappella S et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 1998; 9: 1202-1212
32. Husain S, Andrews NP, Mulcahy D et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97: 716-720
33. Rops AL, van den Hoven MJ, Bakker MA et al. Expression of glomerular heparan sulphate domains in murine and human lupus nephritis. Nephrol Dial Transplant 2007; 22: 1891-1902
34. van Bruggen MC, Walgreen B, Rijke TP et al. Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int 1996; 50: 1555-1564
35. Gourley MF, Austin HA III, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557
36. Grootscholten C, Ligtenberg G, Hagen EC et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70: 732-742
37. Kurogi Y. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 2003; 23: 15-31
38. Salvetti A, Mattei P, Sudano I. Renal protection and antihypertensive drugs: current status. Drugs 1999; 57: 665-693
39. De Albuquerque DA, Saxena V, Adams DE et al. An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int 2004; 65: 846-859
40. Perez DL, De Wit C, Cohen CD et al. Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther 2003; 307: 275-281